세계의 당뇨병성 궤양 치료제 시장 규모 : 치료별, 유형별, 최종사용자별, 지역별, 범위 및 전망

Diabetic Ulcers Treatment Market Size And Forecast

Diabetic Ulcers Treatment Market size was valued at USD 9.17 Billion in 2023 and is projected to reach USD 13.44 Billion by 2031, growing at a CAGR of 5.40% from 2024 to 2031. Diabetic ulcers are chronic wounds that primarily affect the feet and lower extremities of diabetics. These ulcers form as a result of issues such as peripheral neuropathy and poor circulation, which reduce the body's capacity to heal wounds properly. Diabetic ulcers are treated using a multidisciplinary strategy that includes wound care, infection control, glucose management, and advanced therapies such as wound dressings, debridement, and growth factors. In severe situations, surgical intervention or hyperbaric oxygen therapy may be necessary to promote recovery and avoid complications such as amputation.

The increased prevalence of diabetes globally, the demand for efficient diabetic ulcer therapies is likely to increase dramatically. Biotechnology and regenerative medicine advancements are driving innovation in the field, including bioengineered skin substitutes, stem cell therapies, and innovative wound healing agents.

The integration of telemedicine and artificial intelligence in wound care management has the potential to improve patient outcomes by allowing for remote monitoring and individualized treatment strategies. As healthcare systems shift toward preventative measures and early interventions, the market for diabetic ulcer therapy is expected to grow, particularly in regions with growing diabetes populations, such as Asia-Pacific and North America.

Global Diabetic Ulcers Treatment Market Dynamics

The key market dynamics that are shaping the global diabetic ulcers treatment market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The rising incidence of diabetes is a primary driver of the diabetic ulcer treatment market, with roughly 537 million adults affected globally in 2021 and a predicted 783 million by 2045, according to the International Diabetes Federation. This increase has driven up demand for diabetic ulcer treatments since diabetes hinders wound healing, resulting in a higher frequency of chronic ulcers and associated problems such as infections and amputations. As the diabetes population expands, so will the demand for effective wound care treatments to mitigate risks and enhance patient outcomes.

Growing Aging Population:

The growing aging population is a major driver of the diabetic ulcer treatment market, with the World Health Organization predicting that the number of individuals aged 60 and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Diabetes and its consequences, such as poor wound healing and diabetic ulcers, are more common in older persons due to changes in circulation and immunological function caused by aging. As the older population grows, the demand for efficient ulcer treatment solutions will rise to meet the increased risk of chronic wounds and accompanying consequences in this age range.

Increasing Healthcare Expenditure:

Increasing healthcare expenditure, particularly in emerging nations, is propelling the diabetic ulcer treatment market. According to World Bank data, global health expenditure as a proportion of GDP increased from 9.2% in 2000 to 9.8% in 2018. This increased spending enables greater access to innovative treatments, enhanced healthcare infrastructure, and better wound care management. As healthcare budgets expand, more resources are directed into chronic disease management, such as diabetic ulcer treatments, improving patient access to specialized care and novel therapies.

Key Challenges:

High Risk of Infection:

Diabetes ulcers have a high risk of infection, which can complicate therapy and slow recovery. The growing issue of antibiotic resistance exacerbates this problem, making it difficult to properly manage infections. This lengthens treatment times and expenses, restricting the efficacy of current medicines and market growth.

Regulatory Barriers for Advanced Therapies:

Advanced medicines such as stem cells, gene therapy, and bioengineered skin substitutes are subject to demanding regulatory approval. Long and expensive approval processes impede the introduction of novel treatments to the market. Regulatory hurdles impede patient access to potentially life-saving treatments, limiting market growth.

High Treatment Costs:

Treatment costs for advanced diabetic ulcers, including bioengineered skin substitutes and stem cell therapies, might be too expensive for many patients, particularly in underdeveloped nations. The high cost of these treatments limits acceptance and has an impact on overall market growth, as healthcare systems and patients struggle to afford them.

Slow Healing Process:

Diabetic ulcers typically heal slowly due to poor circulation and high blood sugar levels. The delayed rate of healing increases the length and cost of care, putting additional strain on healthcare systems and restricting the scalability of effective treatment solutions, stifling market growth.

Key Trends:

Advances in Wound Care Technologies:

Advances in wound care technology, including bioengineered skin substitutes, growth hormones, and stem cell therapies, enhance the efficiency of diabetic ulcer treatments. These technologies promote faster healing, lower infection risks, and improve patient outcomes, resulting in market development as more healthcare providers use advanced wound treatment systems.

Increasing Adoption of Telemedicine:

Telemedicine is gaining traction in diabetic ulcer treatment as it allows for remote patient monitoring and wound assessment. This trend is especially advantageous for patients who live in remote areas or are unable to travel frequently to the clinic. Telemedicine is being adopted due to its convenience and accessibility, which improves patient compliance and allows for early intervention.

Integration of Artificial Intelligence (AI) in Wound Care:

Artificial Intelligence (AI) is increasingly being used in diabetic ulcer management, assisting healthcare clinicians in predicting wound healing outcomes, tracking treatment progress, and recommending tailored care strategies. AI improves diagnostic accuracy and treatment efficacy, resulting in market growth by enhancing overall patient care and streamlining treatment methods.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetic Ulcers Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global diabetic ulcers treatment market:

North America:

North America currently dominates the global diabetic ulcer treatment market, which is projected to continue in the coming years. One of the primary factors is the high incidence of diabetes in the region, with the Centers for Disease Control and Prevention (CDC) claiming that 37.3 million Americans, or 11.3% of the population, had diabetes in 2021. This figure is expected to increase rapidly, reaching 60.6 million by 2060.

The region has a higher-than-average incidence of diabetic foot ulcers, with a 2022 study in the Journal of the American Medical Association (JAMA) indicating an annual rate of 2.2%, which is projected to rise to 2.5% by 2030. These causes, combined with an aging population, increase the patient pool as older persons are more susceptible to diabetes and accompanying problems.

North America's strong healthcare infrastructure and significant research investments are also driving market expansion. In 2020, the National Institutes of Health (NIH) will invest USD 1.15 Billion in diabetes research, promoting innovation in therapies for diabetic complications such as ulcers. Rising healthcare spending in the United States, expected to reach USD 6.2 Trillion by 2028, supports further investment in advanced ulcer therapies. These characteristics, together with a growing older population and continuing advances in medical technology, are driving North America's leadership in the diabetic ulcer treatment market.

Asia Pacific:

The Asia Pacific region's fastest-growing to the top of the list for diabetic ulcer treatment markets. One of the key factors is the region's increasing prevalence of diabetes, notably in China and India. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, the Western Pacific area had 206 million adults with diabetes in 2021, with the amount expected to climb to 260 million by 2045. This increase dramatically raises the number of individuals at risk of acquiring diabetic complications including foot ulcers, which currently afflict millions.

Furthermore, increased healthcare expenditure and improved healthcare infrastructure are important drivers driving market expansion. According to the World Health Organization (WHO), health spending in the Asia Pacific region has grown at an average annual rate of 6.7%, outperforming economic development, while countries such as China seek to expand healthcare spending to 7% of GDP by 2030. The region's vast and aging population also plays an important role, with the number of persons aged 60 and up predicted to more than double by 2050. This demographic shift, together with increased knowledge of diabetic complications and improved healthcare access, positions the Asia-Pacific area as an essential market for diabetic ulcer therapy in the coming years.

Global Diabetic Ulcers Treatment Market: Segmentation Analysis

The Global Diabetic Ulcers Treatment Market is Segmented on the basis of Treatment, Type, End-User, And Geography.

Diabetic Ulcers Treatment Market, By Treatment

• Wound Care Dressings
• Wound Care Devices
• Active Therapies

Based on Treatment, the market is bifurcated into Wound Care Dressings, Wound Care Devices, and Active Therapies. Wound care dressings dominate as they are widely used to treat a variety of ulcers, including diabetic foot ulcers. Hydrocolloid, foam, and antimicrobial dressings serve to keep the healing environment wet, lower the risk of infection, and promote faster recovery. Active therapies are the fastest-growing area, due to advances in bioengineered skin substitutes, growth factors, and stem cell therapies, which provide more effective options for difficult-to-heal diabetic ulcers, especially in cases when conventional treatments are ineffective.

Diabetic Ulcers Treatment Market, By Type

• Foot Ulcer
• Mouth Ulcer
• Skin Ulcer

Based on Type, the market is segmented into Foot Ulcer, Mouth Ulcer, and Skin Ulcer. The foot ulcer segment is currently dominant due to the high frequency of diabetic foot ulcers among diabetics, which is exacerbated by variables such as neuropathy and poor circulation, all of which increase the risk of foot injuries and infections. The mouth ulcer segment is expanding at a rapid pace, owing to increased knowledge and better diagnostic procedures for diabetic oral complications, as well as an increase in lifestyle-related variables contributing to oral health problems. This development reflects a larger recognition of the need to address all types of ulcers in diabetes individuals in order to enhance overall health.

Diabetic Ulcers Treatment Market, By End-User

• Hospitals And Clinics
• Ambulatory Surgical Centers
• Academic and Research Organizations

Based on End-User, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organizations. Hospitals and clinics dominate the market, owing to their extensive healthcare offerings, superior wound care facilities, and access to specialized medical professionals capable of effectively managing severe diabetic ulcer patients. This component is essential for providing inpatient and outpatient care, guaranteeing a comprehensive approach to treatment. Ambulatory surgery facilities are the fastest-growing group, driven by an increasing desire for outpatient operations, cost-effectiveness, and a growing demand for minimally invasive therapies. These centers are becoming increasingly popular for wound management and ulcer surgery, indicating a shift toward more accessible and efficient patient care.

Key Players

• The "Global Diabetic Ulcers Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• ConvaTec Group Plc, Smith & Nephew Plc, 3M Company, Coloplast AS, B. Braun SE, Medline Industries LP, MiMedx Group, Inc., Organogenesis Inc., URGO Medical, Healthium Medtech, Molnlycke Healthcare, Paul Hartmann AG, and Systagenix Wound Management.
• The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diabetic Ulcers Treatment Market Recent Developments
• In April 2023, 3M Health Care's revolutionary 3M Veraflo therapy, which includes both 3M Veraflo cleanse choice complete dressing and 3M V.A.C. Veraflo cleanse choice dressing, obtained FDA approval for the hydromechanical removal of infectious materials, non-viable tissue, and wound debris. This enabled the company to expand its treatment type offers and launch new treatment types into the market.
• In June 2022, Smith & Nephew will launch a new R&D and manufacturing facility in Hull, UK, for its advanced wound treatment franchise. This strategy enabled the corporation to expand its research operations and enhance its production capacity

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DIABETIC ULCERS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DIABETIC ULCERS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TREATMENT

• 5.1 Overview
• 5.2 Wound Care Dressings
• 5.3 Wound Care Devices
• 5.4 Active Therapies

6 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TYPE

• 6.1 Overview
• 6.2 Foot Ulcer
• 6.3 Mouth Ulcer
• 6.4 Skin Ulcer

7 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals and Clinics
• 7.3 Ambulatory Surgical Centers
• 7.4 Academic and Research Organizations

8 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL DIABETIC ULCERS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 ConvaTec Group Plc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Smith & Nephew Plc
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 3M Company
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Molnlycke Health Care AB
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Coloplast AS
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 B. Braun SE
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Medline Industries LP
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 MiMedx Group Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Organogenesis Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 URGO Medical
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research